FRANKLIN LAKES, N.J., Oct. 17, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of investor relations to his responsibilities, effective immediately.
In this expanded role, Greg will continue as company treasurer and also lead all aspects of communicating progress of BD's strategy to investors and the financial community, including the company's initiatives that drive shareholder value. Rodetis will continue to report to Chris DelOrefice, executive vice president and chief financial officer for BD.
"Greg's deep knowledge of BD, coupled with his expertise of the capital markets and existing relationships with the investment banking community, make him well-positioned to lead our investor relations function and serve as a valued partner to this important stakeholder group as BD continues to deliver on its growth strategy," said DelOrefice.
Rodetis joined BD in 2016 as vice president and assistant treasurer, capital markets. In his current role as treasurer, Rodetis is responsible for leadership and oversight of the company's Treasury function as a strategic partner in supporting business performance, earnings growth and shareholder return. Prior to BD, Greg was with Terex Corporation as the assistant treasurer and prior to this he held roles of progressive responsibility with PepsiCo, Inc., and General Electric Company.
Rodetis holds a Bachelor of Science in Finance from Boston College and is a CFA® Charterholder.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
BD Public Relations | BD Investor Relations |
858.617.2361 | 201.847.6927 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$225.15 |
Daily Change: | -2.02 -0.89 |
Daily Volume: | 1,682,996 |
Market Cap: | US$65.080B |
November 07, 2024 October 30, 2024 October 29, 2024 October 14, 2024 September 26, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB